FIELD: pharmaceutics.
SUBSTANCE: group of inventions relates to the field of pharmaceutics, namely to a combination and a pharmaceutical preparation for the treatment of a neuropsychiatric disorder and late dyskinesia; a combination and a pharmaceutical preparation for the treatment of schizophrenia or a schizoaffective disorder in a subject suffering from late dyskinesia; a combination and a pharmaceutical preparation for the treatment of late dyskinesia related to the injection of an antipsychotic drug; a pharmaceutical preparation for the treatment of late dyskinesia in a subject, which is injected with therapeutically effective amount of the antipsychotic drug; a pharmaceutical preparation for the treatment of late dyskinesia related to the injection of therapeutically effective amount of the antipsychotic drug. All combinations and pharmaceutical preparations contain therapeutically effective amount of the antipsychotic drug and ester of (S)-2-amino-3-methyl-butyric acid and (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-2-yl or its physiologically acceptable salt in the amount of 10-100 mg per a day.
EFFECT: group of inventions provides for an improvement of therapeutical efficiency of the antipsychotic drug when treating a neuropsychiatric disorder due to synergy occurrence between the antipsychotic drug and ester of (S)-2-amino-3-methyl-butyric acid and (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-2-yl or its physiologically acceptable salt.
39 cl, 8 dwg, 4 tbl, 6 ex
